ArticleTheranostics2017
[
Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05557708 (Biodistribution of 68Ga Pentixafor in Patients With Small Cell Lung Carcinoma), which is not on this map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Biodistribution of 68Ga Pentixafor in Patients With Small Cell Lung Carcinoma (SCLC)
Who cites it
63 citing papers in PubMed, 128 citations in OpenAlex.
- Trial
- Role of CXCR4 PET Imaging for the Evaluation of Gliomas: A Comprehensive Literature Review.Cancers · 2026Review
- Selective CXCR4-Targeting Radioconjugates Derived from LY2510924: Evaluation of [Pharmaceuticals (Basel, Switzerland) · 2026Article
- Radiometabolic Therapy in Lymphoma: From Radioimmunotherapy to Emerging Theranostic and Combination Strategies.Cancers · 2026Review
- Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- CXCR4-targeted PET imaging of glioblastoma using [EJNMMI radiopharmacy and chemistry · 2026Article
- Is CXCR4 Theranostics in Oncologic, Cardiovascular, and Inflammatory Diseases Really Happening?Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Development of an Optimized CXCR4-Targeting Theranostic Pair.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Optimization of next-generation CXCR4 ligands for radiotheranostic applications.Frontiers in pharmacology · 2026Review
- Theranostic applications of CXCR4-targeted imaging ligands in lymphoma: integrating diagnosis and precision therapy.American journal of nuclear medicine and molecular imaging · 2026Review
- Targeting CXCR4 with 212Pb/203Pb-Pentixather Significantly Increases Overall Survival in Small Cell Lung Cancer.Radiation research · 2025Article
- CXCR4-targeted theranostics in acute leukemia: disrupting leukemic cell-microenvironment interactions with pentixafor and pentixather.Medical oncology (Northwood, London, England) · 2025Review
- Synthesis andChemMedChem · 2025Article
- Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy.Cancers · 2025Review
- On the automated radiosynthesis of pharmaceutical grade [Scientific reports · 2025Article
- CXCR4-directed endoradiotherapy with [Theranostics · 2025Article
- Chemokine Receptor 4-Targeted PET/CT with [Molecular imaging and biology · 2024Article
- CXCR4 as a therapeutic target in acute myeloid leukemia.Leukemia · 2024Review
- Radiosynthesis and preclinical evaluation of aEJNMMI radiopharmacy and chemistry · 2024Article
- Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.